Despite significant advances in the treatment of multiple myeloma which had led to
unprecedented rates of response and survival, patients still relapse, and cure remains …

Despite many recent advances in therapy, there is still no plateau in overall survival curves
in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach …

PURPOSE Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen–
directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple …

Cell surface expression levels of GPRC5D, an orphan G protein–coupled receptor, are
significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or …

T cell engagers (TCEs) are targeted immunotherapies that have emerged as a promising
treatment to redirect effector T cells for tumor cell killing. The strong therapeutic value of …

Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …

T cell-based immunotherapies have revolutionized treatment paradigms in various cancers,
however, limited response rates secondary to lack of significant T-cell infiltration in the tumor …

Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used
for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and …

Despite advances in treatment for multiple myeloma, the majority of patients ultimately
develop relapsed disease marked by immune evasion and resistance to standard therapy …

Almost all patients with multiple myeloma (MM) will eventually develop disease that has
relapsed with or become refractory to available treatments and will require additional …